In prostate cancer, autoantibody frequency to PARP1/BRCA1/BRCA2 were 2.8% (3/107), 28.0% (30/107) and 4.7% (5/107), 1.9% (2/107), 0.9% (1/107) and 1.9% (2/107) were shown to have autoantibody to PARP1 and BRCA1, PARP1 and BRCA2, or BRCA1 and BRCA2. Here, BRCA2 is linked to prostate carcinoma.